Fondazione I.R.C.C.S. Istituto Neurologico Besta
- Address
- lock Available on a paid plan
Nervous System Diseases and Epilepsy Research
At Fondazione I.R.C.C.S. Istituto Neurologico Besta, clinical trials in Nervous System Diseases focus on focal epilepsy, with research aimed at improving seizure control and understanding how new therapies may benefit adults living with ongoing seizures.
- Studying focal epilepsy as part of broader neurological research
- Evaluating the effectiveness of new treatment options for seizure frequency
- Supporting better care for adults already using anti-seizure medicines
The site’s work in SC Neurologia 7 reflects a strong clinical interest in testing whether emerging therapies can offer improved symptom control and safety for people with difficult-to-manage epilepsy.
Clinical Research in Neurology
This health care research center in Milan is conducting studies centered on focal seizures, with a clear emphasis on assessing treatment effectiveness and advancing practical options for patients with chronic neurological conditions.
- Primary focus on focal seizure disorders
- Exploring new approaches to reduce seizure burden
- Generating evidence to guide future epilepsy treatment
Across its trials, the institute is contributing to research that may help clarify how novel therapies compare with existing care in adults with persistent epilepsy.
Therapy Evaluation in Epilepsy
The clinical trial portfolio at this Italian neurological institute includes work designed to test a new therapy for focal epilepsy, aiming to determine whether it can improve seizure outcomes for adults receiving standard background treatment.
- Epilepsy treatment evaluation
- Focal seizures and symptom control
- Comparing investigational care with existing standard therapy
These studies support ongoing efforts to expand options for patients whose seizures remain a challenge despite current medicines.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 25 therapeutic areas and 15 of 650 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 631 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 174 by active trials.
- 1Merck Sharp & Dohme LLC46active
lock +173 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC98trials
lock +105 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fondazione I.R.C.C.S. Istituto Neurologico Besta
lock Showing 1 of 772 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20290) A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors | Bayer AG, Bayer Consumer Care AG | Phase I | Not Recruiting | Apr 2017 | Jun 2026 |
IMP list
lock Showing 1 of 650 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 136 | Unknown | 2015-11-06 | 2026-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.